Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Third-Party Payers Denied Class Certification in Neurontin, Vioxx Litigation

Executive Summary

Third-party payers may have a tough time getting class certification in suits alleging economic injury from drug purchases given recent rulings in Neurontin and Vioxx litigation

You may also be interested in...



Pfizer Must Pay Kaiser Cost-Difference Of Cheaper Drugs Under Neurontin Marketing Ruling

Judge Patti Saris finds Pfizer fraudulently marketed its anti-epileptic in violation of California law and orders the company to pay Kaiser $95 million.

Third-Party Payers Strike Out in Suits Alleging Off-Label Promotion Injuries

While the pharma industry has plenty of litigation headaches there is good news on one front: courts are tossing out third-party payer suits alleging companies illegally marketed their drugs for off-label use

Third-Party Payers Strike Out in Suits Alleging Off-Label Promotion Injuries

While the pharma industry has plenty of litigation headaches there is good news on one front: courts are tossing out third-party payer suits alleging companies illegally marketed their drugs for off-label use

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel